Welcome to Seer first quarter 2025 earnings conference call. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.

We started Seer with the vision to change the arc of proteomics by providing unprecedented ... which extended the power of Proteograph XT beyond plasma and tissue analysis. We've been very pleased ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

and End Results (SEER) Program. The image on the left shows tiny signaling structures called TIFAsomes (red) being formed in blood cells when cultured with the plasma of an aged healthy 73-year-old ...

Seer Inc. (SEER) reported a robust revenue increase of 37% year-over-year for Q1 2025, reaching $4.2 million. Despite a net loss of $19.9 million, the company’s stock surged 10.42% in ...

Seer Inc. (SEER) reported a robust revenue increase of 37% year-over-year for Q1 2025, reaching $4.2 million. Despite a net loss of $19.9 million, the company’s stock surged 10.42% in aftermarket ...

Seer management emphasized confidence in the company’s technology and market position, supported by strong Q1 instrument demand, robust cash reserves, and execution on large-scale proteomics ...

This study presents a valuable meta-analysis of two independent genome-wide association studies (GWASs) elucidating the role of plasma proteins as biomarkers for improving early detection of prostate ...

The study highlights ALDH4A1’s role as a tumor suppressor by preventing a harmful shift in how cells produce energy.

The abstract, titled "Clinical and biological implications of plasma proteomic patterns in ... us closer to realizing the full potential of proteomics in oncology." ...